View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 28, 2021

MeMed obtains CE mark for Covid-19 tool

MeMed COVID-19 Severity uses machine learning to determine the risk of severe outcomes in patients.

Diagnostic solutions developer MeMed has obtained the European CE mark for its MeMed COVID-19 Severity tool for predicting severe outcomes in patients.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The new host response technology checks for various proteins in a serum sample and uses machine learning to determine the risk that a Covid-19 patient is likely to experience severe outcomes.

The 15-minute test is run on the company’s point-of-need platform, MeMed Key.

This allows doctors to distinguish between patients who may require high-level care and those who can be discharged from the hospital and safely self-isolate home.

Recently, the company has released the clinical data of an immune-protein signature combining trial that showed the solution’s ability to accurately predict severe Covid-19 respiratory failure.

It has also completed an additional independent multinational validation study on MeMed COVID-19 Severity.

MeMed co-founder and CEO Eran Eden said: “I’m excited to begin deploying a pioneering solution to help identify Covid-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation.

“MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics.

“This is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

MeMed plans to offer the tool directly in its priority countries in Europe and through commercial partners in other countries.

In a separate development, iXensor has launched the new PixoHealth Pass Admin App and Web Portal, an integrated Covid-19 screening solution.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU